DX&Vx Signs Research Contract for Development of Lipid Nanoparticle Process for Vaccine Delivery System
DX&VX has signed a research contract with the Pohang University of Science and Technology Industry-Academic Cooperation Foundation (hereinafter POSTECH) to secure global technology for vaccine and new drug development.
On the 1st, DX&VX announced that it recently signed a research contract with POSTECH Industry-Academic Cooperation Foundation for "Membrane process for manufacturing lipid nanoparticles containing genes for gene therapy and vaccines, and manufacturing process for diagnostic color nanoparticles."
Through this research, DX&VX is expected to secure global-level technology for the manufacturing method and equipment of LNPs (lipid nanoparticles), which are used as delivery media for mRNA (messenger ribonucleic acid) vaccines and therapeutics.
LNPs are delivery vehicles that safely transport mRNA to target tissues and cells. They are a core technology of drug delivery systems that help vaccine and new drug substances be delivered inside the human body, enabling the efficacy of vaccines and therapeutics to be expressed. Since global big pharma companies have already secured international patents related to LNPs, it is expected that through this research and development, DX&VX will secure its own technology and take a step closer to vaccine sovereignty.
In particular, by securing technology for the manufacturing and mass production of LNPs as well as the manufacturing equipment necessary for the production process, it is expected that this technology can be utilized in future vaccine production processes.
This research, which will be conducted over a total of three years, was jointly carried out by the Kori Group and POSTECH in the first year, and from this year, DX&VX will continue the research on behalf of the Kori Group. Through the first year of research, patents have already been filed for ▲ manufacturing methods of lipid nanoparticles for mRNA delivery to increase mRNA delivery efficiency ▲ and chamber equipment for manufacturing lipid nanoparticles.
Hot Picks Today
Taking Annual Leave and Adding "Strike" to Profiles, "It Feels Like Samsung Has Collapsed"... Unsettled Internal Atmosphere
- There Is a Distinct Age When Physical Abilities Decline Rapidly... From What Age Do Strength and Endurance Drop?
- Suspended Sentence for Jung Yura on Fraud and Defamation Charges... Both Sides Appeal
- "After Vowing to Become No. 1 Globally, Sudden Policy Brake Puts Companies’ Massive Investments at Risk"
- On Teacher's Day, a Student's Gifted Cake Had to Be Cut into 32 Pieces... Why?
Meanwhile, since 2021, the Kori Group has been conducting joint research with Sichuan University in China on "Hexane vaccine delivery vehicles and platform development," and through mutual exchanges with DX&VX on vaccine development, they are accelerating technology development.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
